DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Ciprofloxacin Hydrochloride is a drug marketed by Akorn Inc, Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Rising, Rubicon, Teligent, Watson Labs Inc, Ani Pharms Inc, Aurobindo Pharma, Barr, Carlsbad, Chartwell, Dr Reddys Labs Ltd, Fosun Pharma, Hikma, Ivax Sub Teva Pharms, Mylan, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique Pharm Labs, Watson Labs, and Yiling Pharm Ltd. and is included in twenty-seven NDAs.
The generic ingredient in CIPROFLOXACIN HYDROCHLORIDE is ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.
A generic version of CIPROFLOXACIN HYDROCHLORIDE was approved as ciprofloxacin hydrochloride by TELIGENT on June 9th, 2004.
Summary for CIPROFLOXACIN HYDROCHLORIDE
Recent Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|Department for International Development, United Kingdom||Phase 4|
|Wellcome Trust||Phase 4|
|Medical Research Council||Phase 4|
Pharmacology for CIPROFLOXACIN HYDROCHLORIDE
|Drug Class||Quinolone Antimicrobial |